CTO1681 30 μg

Preclinical

CCytoAgents, Inc.

CTO1681 30 μg is one of 5 therapeutic programs targeting Cytokine Release Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cytokine Release SyndromeRecruiting

Cytokine Release SyndromePreclinical

Recruiting

Competition

Competitive Landscape

6 competitors in Cytokine Release Syndrome

#DrugCompanyPhaseTrials

Tecvayli

Johnson & Johnson

Phase 2

2 2

Remicade

Johnson & Johnson

Phase 2

1 3

TALVEY

Johnson & Johnson

Phase 2

1 4

Tadekinig Alfa

AAB2 Bio Ltd.

Phase 1

1 5

CTO1681 30 μg

CCytoAgents, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Cytokine Release Syndrome

NCT05905328

Clinical

Trials by Indication[1]

Cytokine Release Syndrome1 trial

Phase 1B/2A Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy

Recruiting·CCytoAgents, Inc.·Preclinical·NCT05905328·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CTO1681 30 μg. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for CTO1681 30 μg. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — CytoAgents, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CCytoAgents, Inc.

CTO1681 30 μg

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cytokine Release Syndrome1 trial

References

Drug Info

Quick Facts

Related News